Sunday, March 16, 2025 | 02:49 AM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

USFDA completes inspection of Dr Reddy's Srikakulam SEZ unit

USFDA recently issued Form 483 with two observations to DRL's another API facility at Srikakulam

reddy, dr reddy's
Premium

Dr Reddy's laboratory

BS Reporter Hyderabad
Hyderabad-based Dr Reddy's Laboratories (DRL) informed the stock exchanges that the US drug regulator has completed the audit of active pharmaceutical ingredients (APIs) manufacturing plant at Srikakulam special economic zone in Andhra Pradesh with no observations.
If the US Food and Drugs Administration (FDA) finds any violation of the Food Drug and Cosmetic Act, it will issue Form 483 and the pharma company should respond to the observations with a corrective action plan and then implement that expeditiously.
The USFDA has recently issued Form 483 with two observations to DRL's another API facility at Srikakulam.

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in